Response to duloxetine in a depressed, treatment-resistant adolescent female

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 889-894

  Delgado, Sergio V ^a   Saldaña, Shannon N ^a   Barzman, Drew H ^a   Coffey, Barbara ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DEXAMPHETAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; METHYLPHENIDATE; QUETIAPINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ADOLESCENT; AGITATION; ANAMNESIS; BEDTIME DOSAGE; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; FAMILY THERAPY; GENERAL CONDITION IMPROVEMENT; HEADACHE; HOSPITAL ADMISSION; HUMAN; MAJOR DEPRESSION; MENTAL HOSPITAL; MONOTHERAPY; NAUSEA; PHOTOTHERAPY; PSYCHIATRIST; REVIEW; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; SUICIDAL IDEATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; PHOTOTHERAPY; SEASONS; THIOPHENES; TREATMENT OUTCOME;

EID: 38549106490     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.1764     Document Type: Review

References (15)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. Washington (DC), American Psychiatric Association, 2000.
2. Bhatia SK, Bhatia SC: Childhood and adolescent depression. Am Fam Physician 75:73-80, 2007.
3. Botteron KN, Geller B: Refractory depression in children and adolescents. Depress Anxiety 5:212-223, 1997.
4. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher M, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA 297:1683-1696, 2007.
5. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880, 2001.
6. Center for Drug Evaluation and Research: Antidepressant use in children, adolescents, and adults. Rockville (Maryland), US Food and Drug Administration. Accessed at http://www.fda.gov/cder/drug/antidepressants/.
7. Cheung AH, Emslie GJ, Mayes TL: The use of antidepressants to treat depression in children and adolescents. CMAJ 174:193-200, 2006.
8. Cymbalta® Package Insert. Indianapolis (Indiana), Eli Lilly and Company, March, 2007.
9. Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB: The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. Am J Psychiatry 162:656-662, 2005.
10. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J, Treatment for Adolescents With Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004.
11. Meesters Y. Light therapy in 3 children with winter depression. Ned Tijdschr Geneeskd. 139:2664-2666, 1995.
12. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB: Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505-2513, 2006.
13. Thase ME, Lu Y, Joliat MJ, Detke MJ: Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator. Eur Neuropsychopharmacol 13(Suppl):S215, 2003.
14. Treatment of SSRI-Resistant Depression In Adolescents (TORDIA), David Brent, M.D., Principal Investigator, Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Accessed September 5, 2007, at http://www.clinicaltrials.gov/ct/show/NCT00018902?order=1/ .
15. Wong DT, Bymaster FP: Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants - potential for greater efficacy or just hype? Prog Drug Res 58:169-222, 2002.